J
James A. Retsema
Researcher at Pfizer
Publications - 40
Citations - 2863
James A. Retsema is an academic researcher from Pfizer. The author has contributed to research in topics: Azithromycin & Antibacterial agent. The author has an hindex of 20, co-authored 40 publications receiving 2808 citations. Previous affiliations of James A. Retsema include Yeshiva University.
Papers
More filters
Journal ArticleDOI
Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection
TL;DR: The significance of extravascular concentrations of azithromycin was further supported in other models of localized infections induced with Escherichia coli or a mixture of Staphylococcus aureus and Bacteroides fragilis and in a comparative study of azathromycin and ciprofloxacin against the salmonella challenge.
Journal ArticleDOI
Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo
TL;DR: Since high and sustained tissue levels of azithromycin occur in animals and humans, it was proposed that it might produce a bactericidal effect in vivo, and this was demonstrated in a lung infection model in mice, designed to mimic the in-vitro killing studies.
Journal ArticleDOI
Preferential concentration of azithromycin in an infected mouse thigh model
TL;DR: The data indicate that delivery of biologically available azithromycin to infected tissues is enhanced by cellular inflammatory processes.
Journal ArticleDOI
Efficacy of Azithromycin for Treating Babesia microti Infection in the Hamster Model
Louis M. Weiss,Murray Wittner,Murray Wittner,Scott Wasserman,Scott Wasserman,Helieh S. Oz,Helieh S. Oz,James A. Retsema,James A. Retsema,Herbert B. Tanowitz,Herbert B. Tanowitz +10 more
TL;DR: Spirogermanium and ciprofloxacin, which have been reported to have antimalarial activity, had no effect on parasitemia or survival in this experimental babesiosis model.
Journal ArticleDOI
Carbenicillin Indanyl Sodium, an Orally Active Derivative of Carbenicillin
TL;DR: Oral administered carbenicillin indanyl sodium protected mice against lethal infections produced by Escherichia coli, Salmonella choleraesuis, Pasteurella multocida, Proteus vulgaris, Staphylococcus aureus, and Streptococcus pyogenes, and against experimental urinary-tract disease in rats.